AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$7.42 USD
-0.13 (-1.72%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $7.40 -0.02 (-0.27%) 7:58 PM ET
1-Strong Buy of 5 1
B Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.42 USD
-0.13 (-1.72%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $7.40 -0.02 (-0.27%) 7:58 PM ET
1-Strong Buy of 5 1
B Value B Growth F Momentum B VGM
Zacks News
Buy These 5 Low Leverage Stocks to Avoid Debt-Related Risk
by Zacks Equity Research
Exorbitant debt financing might even cause a corporation's bankruptcy in the worst-case scenario.
Here's Why You Should Add AngioDynamics to Your Portfolio
by Zacks Equity Research
AngioDynamics (ANGO) continues to benefit from strategic buyouts and strong product portfolio.
AngioDynamics (ANGO) Down 1.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Quest Diagnostics Grows on New Tests Amid Coronavirus Crisis
by Zacks Equity Research
Quest Diagnostics' (DGX) new COVID-19 tests start adding to its Diagnostic information Services business sales.
AngioDyanamics (ANGO) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) fiscal third-quarter results benefit from strong growth across all businesses and higher revenues.
AngioDynamics (ANGO) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 133.33% and 1.98%, respectively, for the quarter ended February 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AngioDynamics (ANGO) Q3 Earnings Expected to Decline
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AngioDynamics (ANGO) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AngioDynamics (ANGO) Down 10.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to AngioDynamics Stock Now
by Zacks Equity Research
AngioDynamics (ANGO) retains fiscal 2020 view; VA revenues soft in fiscal Q2.
AngioDynamics (ANGO) Q2 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
AngioDynamics (ANGO) gains from core Oncology business in the fiscal second quarter, reiterates guidance.
AngioDynamics (ANGO) Beats Q2 Earnings Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 200.00% and -2.61%, respectively, for the quarter ended November 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AngioDynamics (ANGO) Q2 Earnings Expected to Decline
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is AngioDynamics (ANGO) Up 0.9% Since Last Earnings Report?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics Boosts VIT Product Portfolio With New Buyout
by Zacks Equity Research
AngioDynamics (ANGO) is likely to see an expansion of its already existing VIT product portfolio with the buyout of Eximo Medical.
AngioDynamics (ANGO) Q1 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
AngioDynamics (ANGO) keeps fiscal 2020 revenue guidance intact, slashes EPS view.
Luminex Gets FDA Nod for ARIES MRSA Assay, Boosts Platform
by Zacks Equity Research
Luminex (LMNX) receives FDA clearance for the ARIES MRSA assay, which is likely to provide a boost to the company's ARIES platform.
AngioDynamics (ANGO) Q1 Earnings Beat Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 100.00% and -2.32%, respectively, for the quarter ended August 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AngioDynamics (ANGO) Q1 Earnings Expected to Decline
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AngioDynamics (ANGO) Down 8.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics (ANGO) Q4 Earnings Miss, Revenues Top Estimates
by Zacks Equity Research
AngioDyamics (ANGO) gains from solid segmental contributions in fourth-quarter fiscal 2019.
AngioDynamics (ANGO) Lags Q4 Earnings Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of -3.85% and 3.72%, respectively, for the quarter ended May 2019. Do the numbers hold clues to what lies ahead for the stock?
AngioDynamics (ANGO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AngioDynamics Divests NAMIC Portfolio to Medline Industries
by Zacks Equity Research
The NAMIC fluid management portfolio sale clears all of AngioDynamics' (ANGO) outstanding debt.
AngioDynamics IDE Application for NanoKnife Gets FDA Nod
by Zacks Equity Research
AngioDynamics' (ANGO) pilot study is intended to support the approval of a future PMA in the United States.